ARAY Earnings Q2 2026: Accuray Reports Quarterly Results and Outlook

Accuray Company Overview and Business Context

Accuray designs, develops, and sells advanced radiation therapy and radiosurgery systems used in the treatment of tumors throughout the body. The company's two flagship platforms — the CyberKnife System and the Radixact System — are installed in cancer treatment centers around the world. Accuray generates revenue through both product sales and a recurring service revenue stream tied to maintenance contracts and upgrades.

Heading into Q2 FY2026, Accuray has been navigating a challenging environment that includes hospital capital expenditure constraints, foreign currency headwinds, and increasing competition from larger medical device companies such as Varian (a Siemens Healthineers company) and Elekta. Despite these pressures, the company has focused on expanding its installed base, driving adoption of its latest technology platforms, and growing its higher-margin service business.

With a market capitalization of approximately [MARKET_CAP] and shares trading near [CURRENT_PRICE], Accuray remains a small-cap stock that carries both significant upside potential and notable risk for investors (per market data as of the reporting date).

Q2 FY2026 Revenue Performance

Total Revenue Breakdown

For the second quarter of fiscal year 2026, Accuray reported total revenue of [Q2_REVENUE], compared to analyst consensus estimates of [CONSENSUS_REVENUE] (according to analyst estimates compiled by Refinitiv). This result represented a [YEAR_OVER_YEAR_CHANGE]% change compared to the same quarter in the prior fiscal year.

Breaking down the revenue by segment, product revenue came in at [PRODUCT_REVENUE], while service revenue totaled [SERVICE_REVENUE]. The service segment has historically been a more stable and predictable revenue contributor, and investors have been monitoring whether Accuray can continue to grow this recurring revenue base as a percentage of total sales.

Geographic Revenue Mix

Accuray's revenue is geographically diversified, with significant contributions from the Americas, Europe-Middle East-Africa (EMEA), and the Asia-Pacific region. In Q2 FY2026, the geographic breakdown showed [AMERICAS_REVENUE] from the Americas, [EMEA_REVENUE] from EMEA, and [APAC_REVENUE] from Asia-Pacific (per the company's earnings release). Foreign currency fluctuations continued to impact reported results, with management noting [FX_IMPACT] in currency effects during the quarter.

The Asia-Pacific region, particularly China and Japan, has been a key growth driver for Accuray in recent years. Investors should continue to monitor geopolitical developments and regulatory approvals in these markets, as they can materially affect order flow. For more on how currency movements impact multinational stocks, see our forex impact on earnings guide.

Profitability and EPS Analysis

Gross Margins

Accuray reported a gross margin of [GROSS_MARGIN]% in Q2 FY2026, compared to [PRIOR_YEAR_GM]% in the year-ago period. Product gross margins came in at [PRODUCT_GM]%, while service gross margins were [SERVICE_GM]%. The company's ongoing efforts to improve manufacturing efficiency and shift toward higher-margin service contracts have been central to its margin improvement strategy.

Management has emphasized that gross margin expansion remains a top priority. Mix shifts between product and service revenue, as well as the proportion of higher-margin CyberKnife sales versus Radixact sales, can create quarter-to-quarter variability in this metric.

Operating Expenses and Net Income

Total operating expenses for the quarter were [OPEX], reflecting the company's investment in research and development as well as sales and marketing initiatives. Research and development spending totaled [RD_EXPENSE], underscoring Accuray's commitment to innovation in treatment planning software and next-generation hardware capabilities.

On the bottom line, Accuray reported GAAP net income (loss) of [NET_INCOME] for the quarter, translating to earnings per share of [EPS]. This compared to the analyst consensus EPS estimate of [CONSENSUS_EPS] (according to estimates compiled by Bloomberg). On a non-GAAP adjusted basis, EPS was [ADJ_EPS], which excludes stock-based compensation and certain restructuring charges.

EBITDA and Cash Flow

Adjusted EBITDA for Q2 FY2026 was [ADJ_EBITDA], representing an EBITDA margin of [EBITDA_MARGIN]%. Free cash flow for the quarter came in at [FREE_CASH_FLOW], and the company ended the period with cash and cash equivalents of [CASH_POSITION] on its balance sheet (per the company's SEC filings).

Cash flow generation is particularly important for small-cap medical device companies like Accuray, as it determines the company's ability to fund R&D, service debt obligations, and potentially return capital to shareholders without dilutive equity offerings.

Order Backlog and Forward Indicators

One of the most closely watched metrics for Accuray is its gross order volume and backlog. In Q2 FY2026, the company reported gross orders of [GROSS_ORDERS], with a total backlog of [BACKLOG] at the end of the quarter. The backlog provides visibility into future revenue and is a leading indicator of the company's commercial momentum.

New orders were driven by [ORDER_DRIVERS], with management highlighting particular strength in [STRONG_REGIONS_OR_PRODUCTS]. The book-to-bill ratio — a measure of orders received relative to revenue recognized — was [BOOK_TO_BILL] for the quarter, providing [POSITIVE_OR_CAUTIOUS] signals about near-term revenue trajectory.

Investors should note that order timing can be lumpy in the capital equipment space, and a single large hospital system order can meaningfully swing quarterly order figures. Evaluating trends over multiple quarters provides a more reliable picture of demand.

Management Guidance and Strategic Outlook

Updated Full-Year FY2026 Guidance

During the earnings call, Accuray's management team provided updated guidance for the full fiscal year 2026. The company now expects total revenue in the range of [LOW_REVENUE_GUIDE] to [HIGH_REVENUE_GUIDE], compared to the prior guidance range of [PRIOR_LOW_GUIDE] to [PRIOR_HIGH_GUIDE]. Adjusted EPS guidance was set at [LOW_EPS_GUIDE] to [HIGH_EPS_GUIDE] for the full year (per the company's earnings release and conference call transcript).

Management cited [GUIDANCE_FACTORS] as key factors influencing the updated outlook. CEO [CEO_NAME] noted during the earnings call that the company remains focused on driving installed base growth, increasing service revenue penetration, and advancing its technology roadmap to maintain competitive differentiation.

Strategic Initiatives

Accuray continues to invest in several strategic initiatives that could shape its long-term growth trajectory. These include the ongoing development of artificial intelligence-enhanced treatment planning capabilities, expansion into emerging markets with growing cancer treatment infrastructure, and efforts to establish new clinical evidence supporting the efficacy of its platforms in additional tumor indications.

The company has also been working to strengthen its balance sheet and improve operational efficiency. Any progress on debt reduction or margin expansion would likely be viewed favorably by the investment community, given the stock's valuation sensitivity to profitability milestones.

Analyst Reactions and Market Response

Following the release of ARAY earnings Q2 2026, shares of Accuray moved [STOCK_DIRECTION] by approximately [STOCK_MOVE]% in [PRE_OR_POST]-market trading. The stock currently trades at a price-to-earnings ratio of [PE_RATIO] on a trailing twelve-month basis and [FORWARD_PE] on a forward basis (per market data).

Analyst reactions were [MIXED_POSITIVE_NEGATIVE], with [NUM_ANALYSTS] analysts maintaining coverage on the stock. The consensus price target stands at [CONSENSUS_PT], implying [UPSIDE_DOWNSIDE]% from the current trading price (according to analyst estimates compiled by Refinitiv). Key themes from analyst commentary included [ANALYST_THEMES].

For investors evaluating ARAY as a potential portfolio addition, the Q2 results should be viewed in the context of the company's multi-year transformation story. While quarterly results can fluctuate, the longer-term trends in service revenue growth, margin expansion, and order backlog provide a more meaningful measure of the company's strategic progress. Learn more about evaluating small-cap medical device stocks in our small-cap investing strategies guide.

Key Risks to Monitor

Despite any positive developments in the quarter, investors should remain aware of several material risks facing Accuray. Competition from significantly larger and better-capitalized rivals remains intense, and hospital purchasing decisions can be delayed by macroeconomic uncertainty or changes in healthcare reimbursement policies.

Additional risks include foreign currency exposure given Accuray's international revenue mix, potential supply chain disruptions affecting component availability and manufacturing costs, and the inherent execution risk associated with technology platform transitions. The company's relatively high debt levels compared to its market capitalization also warrant monitoring, particularly in a rising interest rate environment.

• Competitive pressure: Varian and Elekta continue to invest heavily in next-generation platforms
• Reimbursement risk: Changes in Medicare or international payer policies could impact demand
• Currency headwinds: A strong U.S. dollar can reduce the value of international revenues
• Capital allocation: Balancing R&D investment with debt management and profitability targets
• Order lumpiness: Large capital equipment orders can create significant quarter-to-quarter volatility

Bottom Line: What ARAY Q2 2026 Earnings Mean for Investors

The ARAY earnings Q2 2026 report provides investors with an important checkpoint on Accuray's journey toward sustainable profitability and growth. The quarter's results — particularly trends in service revenue, gross margins, and order backlog — offer critical data points for evaluating whether the company's strategic initiatives are translating into financial results.

For long-term investors, the key question remains whether Accuray can carve out a durable competitive position in the radiation oncology market while achieving the scale necessary to generate consistent free cash flow. The updated full-year guidance and management commentary from the earnings call provide the most current framework for assessing that trajectory.

As always, investors should consider their own risk tolerance, portfolio diversification needs, and investment time horizon before making decisions based on a single quarter's earnings report. Monitoring subsequent quarters for trend confirmation will be essential.